Patient P-01417
Therapy response
Improving
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
89%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 57 GI-04 recommended — GI Support Protocol GI-04
- Day 58 Patient accepted — Started GI-04 in the companion
- Day 64 ME-01 recommended — Monitoring Escalation ME-01
- Day 65 Patient accepted — Started ME-01 in the companion
- Day 66 GI symptom burden −20% vs expected — GI Support Protocol GI-04
- Day 68 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 72 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 48.
Primary contributors, last 14 days
- GI instability+10
- Treatment adherence-3
- Inflammatory activity+2
- Nutritional resilience-2
What helped?
- GI Support Protocol GI-04Day 57Result: symptom burden −20%
- Monitoring Escalation ME-01Day 64Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
59%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 38/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 61
- Autonomic recovery ↓45
- WearableResting HR 77 bpm
- Wearable1,811 steps/day
- Mucosal barrier integrity ↓20
- Daily logGI symptom score 60 and rising
- Drug metabolism and exposure ↑20
- BloodToxicity index 58
DNA
Fictional pharmacogenomic panel
- CYP2D6 Rapid metabolizerExpected exposure
Microbiome
Shannon diversity 3.1 · butyrate capacity 38/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 53 ms
- Sleep
- 6.9 h
- Steps
- 2,093
- Resting HR
- 76 bpm
Daily log: GI score 60, nutritional resilience 37, adherence 42.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.